Tangram Announces First Participant Dosed in Phase 1 Trial of TGM-148, a Novel Investigational RNAi Medicine for Bleeding Disorders
TGM-148 is designed to combine hemostatic efficacy with a favorable safety profile and low treatment burden Tangram’s second asset to...
ADM Tronics Reports Second Quarter of Fiscal Year 2027 Results